Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EGFR-IN-45 is a potent pan-inhibitor of the epidermal growth factor receptor (EGFR), acting on EGFR (IC50: 0.4 μM) and CDK2 (IC50: 1.6 μM). EGFR-IN-45 also inhibits the topoisomerases Topo I and Topo II. EGFR-IN-45 blocks the cell cycle of cancer cells in the pre-G1 phase and induces apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | EGFR-IN-45 is a potent pan-inhibitor of the epidermal growth factor receptor (EGFR), acting on EGFR (IC50: 0.4 μM) and CDK2 (IC50: 1.6 μM). EGFR-IN-45 also inhibits the topoisomerases Topo I and Topo II. EGFR-IN-45 blocks the cell cycle of cancer cells in the pre-G1 phase and induces apoptosis. |
Molecular Weight | 473.53 |
Formula | C28H23N7O |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.